Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Morgan Stanley arrives at its October 14 Q3 print with the stock down 12% over the past month, analysts still cutting targets, and a put/call ratio that has actually pulled back from its late-September peak, suggesting the most acute phase of pre-earnings hedging may be behind the market.
The options picture has shifted since the previous notes flagged near-52-week extremes. The put/call ratio has eased to 1.51, down from the 1.62 reading recorded on September 28 and meaningfully off the 52-week high of 1.63. That still sits above the 20-day mean of 1.54, but the z-score of negative 0.59 means the current ratio is actually slightly below its recent average, not above it. The defensive positioning that dominated late September has moderated. Borrowing conditions remain irrelevant to the bear thesis here: short interest is less than 1% of the free float, borrow availability is effectively unlimited, and the lending market carries no squeeze pressure whatsoever. The short score of 30.8 has been flat all week. This is not a short-interest story.
The analyst story is more consequential, and it moved again this week. BMO Capital's Brennan Hawken cut his target to $215 from $250 on October 6, keeping an Outperform rating. A day earlier, UBS's Erika Najarian trimmed to $236 from $260, also holding at Buy. Both cuts are significant because they come from analysts who remain constructive on the name, which means the reductions reflect revised earnings assumptions rather than a change of heart on the franchise. Evercore ISI and Citigroup moved the same way in the final days of September, and Wells Fargo had already pulled its target to $223 earlier that week. The direction of travel across the Street is unanimous: lower targets, unchanged ratings. The mean consensus has drifted to roughly $237, which at first glance implies around 24% upside from $191. That figure warrants caution, however, since several of the higher targets in the consensus were set in July when the stock was trading above $215. The more relevant data points are the fresh cuts, which are clustering in the $210 to $236 range. At $191, the stock has already moved most of the way to where the cautious end of the Street is anchored.
The bull case centres on Morgan Stanley's franchise breadth. The Q1 print showed record Institutional Trading revenue of $8.6 billion, Wealth Management delivering $8.5 billion with $118 billion of net new assets, and a core ROATCE of 28%. Bears point to the same market sensitivity: a business that produces record trading revenue in a strong tape can give it back quickly if conditions turn. Investment Management was already soft in Q1, with revenue down 4.3% year-on-year. The stock's PE multiple has compressed to around 14.3 times, down roughly 1.9 points over the past month, and price-to-book has fallen to 2.59, off 0.37 points over 30 days. Those moves reflect the stock's decline more than any fundamental re-rating, but they do put the entry point on a different footing than it was in September.
Mitsubishi UFJ Financial Group remains the dominant shareholder with around 24% of shares. Its 13D filings classify it as an activist on the register, though in practice the relationship is structural rather than adversarial, dating to the 2008 capital injection. MUFG has been trimming slowly under a 10b5-1 plan, disposing of roughly 1.3 million shares in September at prices around $212.57. CFO Sharon Yeshaya sold just over $3.4 million of stock in mid-July at prices above $222, also outside a formal plan. Neither sale is alarming in isolation, but the absence of any open-market buying from the executive ranks into a 12% drawdown is worth noting.
The last two earnings reactions offer a mixed reference point. The Q1 2026 print in July produced a 4.1% single-day decline and a 4% loss over the following five sessions. The May print before that was effectively flat on the day, followed by a 3.4% five-day gain. What to watch on October 14 is whether Wealth Management's net new asset momentum has held, whether Investment Management has stabilised after Q1's revenue decline, and whether the trading run rate from a volatile third quarter shows up in the numbers or gets offset by weaker advisory fees.
See the live data behind this article on ORTEX.
Open MS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
